# Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP

> **NIH NIH U19** · WASHINGTON UNIVERSITY · 2024 · $44,108,652

## Abstract

SUMMARY.
The Vaccines and Therapeutic Antibodies to Respirovirus, Rubulavirus, Peribunyavirus and
Phenuivirus (R2P2) ReVAMPP Center will utilize both well-defined and novel approaches to develop
prototype vaccines and human monoclonal antibody (mAb)-based treatments for rapid response to viruses
from the Paramyxoviridae, Peribunyaviridae and Phleboviridae families. R2P2 is composed of four primary
Research Projects: two that collectively focus on prototype viruses of the Paramyxoviridae family including
human parainfluenza viruses 3 and 1 (HPIV3, HPIV1), and human and bat mumps virus (MuV, BatMuV); and
two that focus on prototype viruses of the Bunyavirales order including the Peribunyaviridae Oropouche (OROV)
and La Crosse (LACV) and the Phenuiviridae Rift Valley Fever virus (RVFV) and Toscana virus (TOSV). Each
project in R2P2 follows a parallel structure and makes use of the principles of reverse vaccinology, where insights
from the structural and function studies will provide a framework to understand the molecular correlates of
immunity and antigenicity and provide a roadmap for designing optimized immunogens. The foundational studies
carried out in this ReVAMPP center will fill gaps in basic understanding of viral entry and will also inform how to
extend the stabilization approaches successfully used to advance vaccines against agents with Class I fusogens
(e.g., RSV), to those with Class II. A key R2P2 feature is that all four projects compare the same three vaccine
platforms: protein subunit, mRNA, and chimeric VSV, allowing for cross comparisons that will rapidly yield
information about platform performance in translating to related pathogens. The questions of which antigen
stabilization paradigms, and which vaccine platforms are most amenable to generalizing from the prototype
pathogens will be answered in depth and breadth by these comparisons across virus families. We assembled a
collaborative team of world-renowned experts on viral envelope protein structure and function, leading
immunologists, vaccinologists with extensive experience in industry and regulatory issues, and industry partners
(e.g., Modena, GSK). The inclusion of junior investigators with exceptional promise is designed to ensure the
engagement of the next generation of leaders in viral glycoprotein biology, viral immunology and vaccinology in
pandemic preparedness. These Projects are served by an Administrative Core (Core A), a Data Management
Core (Core B), and three Scientific Cores that perform structural biology, biophysics and protein engineering
(Core C), antibody isolation and assessment (Core D), and correlates of immune protection (Core E) experiments
in collaboration with multiple projects. The knowledge accumulated in this project and the robustness of the
approaches implemented to develop prototype vaccines will be expanded to different viruses of the same families
to evaluate their potential and broad applicability against emerging viruses of the Bunyavir...

## Key facts

- **NIH application ID:** 10863691
- **Project number:** 1U19AI181984-01
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Anne Moscona
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $44,108,652
- **Award type:** 1
- **Project period:** 2024-09-11 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10863691

## Citation

> US National Institutes of Health, RePORTER application 10863691, Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP (1U19AI181984-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10863691. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*